MDS

4
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
3 programs
1
2
ASTX727Phase 21 trial
SGI-110 administrationPhase 21 trial
GuadecitabinePhase 1/21 trial
Active Trials
NCT01261312CompletedEst. Jul 2016
NCT04857645CompletedEst. Apr 2025
NCT02197676CompletedEst. Apr 2018
Novartis
NovartisBASEL, Switzerland
3 programs
1
Azacitidine and LDE255Phase 11 trial
Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMMLN/A1 trial
transplantationN/A1 trial
Active Trials
NCT06267898Completed222Est. May 2015
NCT02757989Completed79Est. Jun 2024
NCT02323139Completed23Est. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astex PharmaceuticalsASTX727
Astex PharmaceuticalsSGI-110 administration
Astex PharmaceuticalsGuadecitabine
NovartisAzacitidine and LDE255
Novartistransplantation
NovartisNon Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

Clinical Trials (6)

Total enrollment: 324 patients across 6 trials

NCT04857645Astex PharmaceuticalsASTX727

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Start: Jun 2021Est. completion: Apr 2025
Phase 2Completed
NCT02197676Astex PharmaceuticalsSGI-110 administration

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Start: Aug 2014Est. completion: Apr 2018
Phase 2Completed
NCT01261312Astex PharmaceuticalsGuadecitabine

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Start: Jan 2011Est. completion: Jul 2016
Phase 1/2Completed
NCT02323139NovartisAzacitidine and LDE255

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

Start: Feb 2015Est. completion: Aug 201823 patients
Phase 1Completed
NCT02757989Novartistransplantation

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Start: May 2016Est. completion: Jun 202479 patients
N/ACompleted
NCT06267898NovartisNon Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

Start: Nov 2009Est. completion: May 2015222 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space